Trastuzumab: A review of its use in HER2-positive advanced gastric cancer

Drugs

Volumn 73, Issue 14, 2013, Pages 1605-1615

  Sanford, Mark ^a  

^a Adis   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROPYRIMIDINE; FLUOROURACIL; TRASTUZUMAB;

ABDOMINAL PAIN; ADVANCED CANCER; ANGIONEUROTIC EDEMA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BODY WEIGHT DISORDER; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PAIN; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOMYOPATHY; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INTERACTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; FATIGUE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; GASTRITIS; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LUNG HYPOPLASIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEPHROTIC SYNDROME; NONHUMAN; OLIGOHYDRAMNIOS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY DISTRESS; REVIEW; RHINOPHARYNGITIS; STEADY STATE; STOMACH CANCER; STOMATITIS; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; TUMOR XENOGRAFT; VOMITING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84890523681     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0119-y     Document Type: Review

References (35)

1. Delanoit T. Latest developments and emerging treatment options in the management of stomach cancer. Cancer Manag Res. 2011;3(1):257-66
2. Bang YJ. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol. 2012;46(8):637-48
3. Rüschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637-50
4. Jørgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer-a systematic analysis of data from the literature. J Cancer. 2012;3:137-44
5. Janjigian YY, Werner D, Pauligh C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23(10):2656-62
6. European Medicines Agency. Herceptin 150 mg powder for concentrate for solution for infusion: summary of product characteristics. http://www. emea. europa. eu/docs/en-GB/document- library/EPAR-Product-Information/human/000278/ WC500074 922. pdf. Accessed 7 August 2013
7. Genentech, Inc. Herceptin- (trastuzumab): US prescribing Information 2010. http://www. accessdata. fda. gov/drugsatfda-docs/ label/2010/ 103792s5256lbl. pdf. Accessed 7 August 2013
8. Chugai Pharmaceutical Co., Ltd. Anti-cancer agent, Herceptin- obtained approval for additional indication of advanced or recurrent gastric cancer overexpressing HER2, not amenable to curative resection [media release]. 10 March 2011. http://www. chugai-pharm. co. jp
9. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39-51
10. Croxtall JD, McKeage K. Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs. 2010;70(17):2259-67
11. Kim SY, Kim HP, Kim YJ, et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol. 2008;32(1):89-95
12. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol. 2007;59(6):795-805
13. Yamade M, Sugimoto M, Nishino M, et al. Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence. Anticancer Res. 2012;32(1):105-14
14. Li X-L, Yi S-Q, Xu J-M, et al. The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-fluorouracil or cisplatin on gastric cancer cell lines. Cancer Invest. 2010;28(10):1038-47
15. Yoshida R, Tazawa H, Hashimoto Y, et al. Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human gastric cancer cells. Cancer Immunol Immunother. 2012;612:1905-16
16. WainbergZA,AnghelA,RogersAM, et al. Inhibition ofHSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. Mol Cancer Ther. 2013;12(4):509-19
17. Shi M, Yang Z, Hu M, et al. Catecholamine-induced beta2-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression. J Immunol. 2013;190(11):5600-8
18. Satoh T, Omuro Y, Sasaki Y, et al. Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer. Cancer Chemother Pharmacol. 2012;69(4):949-55
19. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97
20. Sawaki A, Ohashi Y, Omuro Y, et al. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer. 2012;15(3):313-22
21. Satoh T, Leon J, Lopez RI, et al. Quality of life results from a phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer [abstract no. 7]. American Society of Clinical Oncology: Gastrointestinal Cancers Symposium; 22-24 January 2010; Chicago, IL, USA
22. Ohtsu A, Wang L, Lim H, et al. Quality of life results from a phase III study of trastuzumab plus chemotherapy as first-line therapy in patients with HER2-positive advanced gastric and gastro-esophageal junction cancer [abstract O-0011]. Ann Oncol. 2010; 21 Suppl.:vi14
23. Kang YK, Shen L, Lichinitser M, et al. Self-rated pain assessment by patients with HER2-positive advanced gastric/GEJ cancer treated with 5-FU/capecitabine and cisplatin with or without trastuzumab: exploratory QOL analysis from the phase III ToGA study [abstract Sa1016]. Gastroenterology. 2011;140(5 Suppl. 1):S204
24. Chung HC, Bang Y, Van Cutsem E, et al. (Q)-TWiST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/ FP alone as first-line therapy for advanced HER2-positive gastric cancer [abstract no. 4048]. J Clin Oncol. 2010; 28(15 Suppl. )
25. Okines A, Verheij M, Allum W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and followup. Ann Oncol. 2010;21(Suppl 5):v50-4
26. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer (version 2. 2013). http://www. nccn. org/professionals/physician-gls/pdf/gastric. pdf. Accessed 7 August 2013
27. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver 3). Gastric Cancer. 2011. doi:10. 1007/s10120-011-0042-4
28. Sano T, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Japanese Gastric Cancer Association. Gastric Cancer. 2011;14:97-100
29. Gencer D, Al-Batran SE, Dada R, et al. Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval. J Cancer Res Clin Oncol. 2013;139(2):337-45
30. Norman G, Rice S, Spackman E, et al. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. Health Technol Assess (Winchester, England). 2011;15(Suppl 1):33-42
31. Holden J, Garrett Z, Stevens A. NICE guidance on trastuzumab for the treatment of HER2-positive metastatic gastric cancer. Lancet Oncol. 2011;12(1):16-7
32. Wu B, Ye M, Chen H, et al. Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clin Ther. 2012;34(2):468-79
33. Hoffmann-La Roche, Ltd. A study of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy in patients with HER2-positive metastatic gastroesophageal junction or gastric cancer. http://clinicaltrials. gov/ct2/show/NCT01774786. Accessed 28 May 2013
34. Hoffmann-La Roche, Ltd. A study of trastuzumab emtansine versus taxane in patients with advanced gastric cancer. http:// clinicaltrials. gov/ct2/show/NCT01641939. Accessed 28May 2013
35. Hoffmann-La Roche, Ltd. HELOISE Study: a study of Herceptin (trastuzumab) in combination with cisplatin/capecitabine chemotherapy in patients with HER2-positive metastatic gastric or gastro-esophageal junction cancer. http://clinicaltrials. gov/ct2/ show/NCT01450696. Accessed 28 May 2013.